Cipla Stock Correction: Opportunity Knocks as Bad News Priced In, Says Analyst

• Systematix analyst Vishal Manchanda sees Cipla's recent stock correction as a buying opportunity, believing most negative news is already factored into the price.
• Cipla's US market, contributing 27% of sales, delivered record revenue of $934 million in FY25 but faces challenges in FY26.
• Key issues include a temporary halt in Lanreotide supply due to manufacturing partner's facility observations and intensified competition for a generic cancer drug.
• Despite challenges, Manchanda notes Cipla trades at 21x FY27 earnings, below its 10-year median of 30x, suggesting limited downside.
• Management targets a $1 billion US revenue run rate by Q4 FY27, with potential for upside surprise if key approvals materialize.

Why It Matters: Cipla's stock correction presents a buying opportunity as most negative factors are priced in, with future growth potential.